Vidac Pharma is one of the biotech shooting stars on the German stock market, with its share price having risen by over 230% in the last six months. The Company is now receiving a reinvestment of EUR 600,000 from shareholders to advance the clinical trials of its cancer drug candidates. Vidac will use the funds to conduct a series of clinical trials, including a second Phase 2b clinical trial of VDA-1102 in advanced actinic keratosis (AK), an early form of skin cancer that can develop into cutaneous squamous cell carcinoma (CSCC). Vidac is initiating the regulatory preparations for this study and has also signed a contract with the research dock CRO. Prof. Dr. Thomas Dirschka, one of the world's leading experts on AK and head of the leading dermatological research institute, CentroDerm GmbH, will be the principal investigator.
News & Events